Positive urinary fluorescence in situ hybridization indicates poor prognosis in patients with upper tract urothelial carcinoma

Bao Guan1,2,*, Yicong Du1,2,*, Xiaohong Su1,2,*, Zhenpeng Cao1, Yifan Li1,2, Yonghao Zhan1,2, Ding Peng1,2, Gengyan Xiong1,2, Dong Fang1,2, Yi Ding1, Shiming He1,2, Yanqing Gong1,2, Qun He1,2, Xuesong Li1,2 and Liqun Zhou1,2

1Department of Urology, Peking University First Hospital, Xicheng, Beijing, China 2Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China

*These authors contributed equally to this work

Correspondence to: Xuesong Li, email: pineneedle@sina.com
Liqun Zhou, email: zhoulqmail@sina.com

Keywords: fluorescence in situ hybridization (FISH); upper tract urothelial carcinoma (UTUC); recurrence; prognosis

Received: July 20, 2017 Accepted: November 09, 2017 Epub: January 04, 2018 Published: March 06, 2018

ABSTRACT

Here, we evaluated the potential contribution of fluorescent in situ hybridization (FISH) as a prognostic risk factor of bladder recurrence and survival in patients with upper tract urothelial carcinoma (UTUC). A total of 159 UTUC patients were enrolled in this study from January 2012 to May 2016. The 159 voided urine samples before surgery were analyzed using the UroVysion® kit to detect the copy numbers of chromosomes 3, 7, 17, and 9p21 (p16). Patients were classified using an optimal cutoff value of chromosomes 3, 7, 17, and 9p21. Cox’s proportional hazards regression model was used to assess the prognostic value of FISH for bladder recurrence and survival. We found that 27 (17.6%) patients experienced bladder recurrence and 26 (16.4%) patients died from cancer, with a median follow-up of 27 months. The patients with positive FISH result were more likely to present bladder recurrence (p = 0.077). However, positive FISH was not associated with cancer specific-free survival (CSS) (p = 0.944). Tumor multifocality, the percentage of abnormal chromosome 3 > 5%, chromosome 7 > 6%, chromosome 17 > 11% and deletion of p16 > 4% were significant prognostic risk factors for BRFS in univariate analysis. In multivariate analysis, only tumor multifocality (hazard ratio [HR] = 3.487, 95%CI: 1.605–7.576, p = 0.002) and the percentage of p16 loss > 4% were both prognostic risk factors for bladder recurrence (HR = 3.487, 95%CI: 1.605–7.576, p = 0.002). These data consider that the urinary FISH test could be a powerful tool in predicting the risk of bladder recurrence in patients with UTUC.

INTRODUCTION

Upper tract urothelial carcinoma (UTUC) is a relatively uncommon malignant tumor [1]. Though the standard treatment method, radical nephroureterectomy (RNU), could remove primary tumor lesions, the probability of bladder recurrence and progression remain high [1–3]. Consequently, it is necessary to find novel biomarkers to predict oncological outcomes.

Fluorescence in situ hybridization (FISH) analysis which uses nucleic acid probes marked with fluorescence to evaluate cells in the voided urine for chromosomal alterations and be widely applied to the field of cancer diagnosis. [4–7], and we had identified its high sensibility and prediction for advanced UTUC [8]. We used UroVysion® FISH test ((Abbott Molecular, des Plaines, IL, USA)) to measure the percentage of particular copy number variation of chromosomes 3, 7, 17, and 9p21 (p16) in the urine. Recently, several studies had reported that FISH could be used as an aid to predict prognosis in bladder cancer patients [9–11], but its prognostic value had not yet been confirmed in UTUC patients. Therefore, the prognostic capacity of FISH was studied by us in a single and relatively high-volume center in China.
RESULTS

Patient and tumor characteristics

There were 78 (49.1%) male and 81 (50.9%) female patients, and the median age was 70 years (range: 31–87 years). Among 159 patients, non-muscle invasive (≤ pT1) and muscle invasive (≥ pT2) UTUC patients were 82 (51.5%) and 77 (48.5%), respectively, while low and high grade patients were 86 (54.1%) and 73 (45.9%), respectively (Table 1).

FISH results

Clinical outcomes and cutoff value are described in Table 2. The median percentage of abnormal chromosome 3, 7, 17 and p16 loss were 7% (0–46%), 7% (0–38%), 8% (0–53%) and 7% (0–65%), respectively. According to the area under the curve (AUC) from the receiver operating characteristic curve (ROC) for intravesical relapse, we defined the cutoff values of the proportion of aberrant chromosomes 3, 7, and 17 and loss of p16. The cutoff values were 5% for chromosome 3, 6% for chromosome 7, 11% for chromosome 17 and 4% for p16 loss. According to the cutoff values of preoperative factors, all patients were allocated to 2 classes.

The association of FISH with pathological tumor characteristic is shown in Table 3. Patients with percentage of chromosome 17 > 11% and loss of p16 > 4% were associated with high stage and grade. Univariate and multivariate binary logistic analysis found only the percentage of abnormal chromosome 17 was associated with high stage and grade. Univariate and multivariate analysis are shown in Table 4. The results of FISH analysis showed that 57 of 159 patients were negative, of 6 patients had histologically verified bladder recurrence; 102 patients were positive, of 22 had bladder recurrence. Kaplan–Meier analysis showed that patients with positive FISH result were more likely to present bladder recurrence (p = 0.077, Figure 1A). However, positive FISH was not related to cancer specific-free survival (CSS) (p = 0.944, Figure 1B).

Oncological outcomes

The median follow-up was 27 months (range: 3–55). The median time to bladder relapse and time to death from UTUC was 11 (range: 1–43 months) months and 15.5 (range: 3–38 months) months, respectively. During follow-up, 31 (19.5%) patients died, 26 (16.4%) of them due to UTUC; 28 (17.6%) patients experienced bladder recurrence.

Variables associated with CSS and BRFS on univariate and multivariate analysis are shown in Table 4. The results of FISH analysis showed that 57 of 159 patients were negative, of 6 patients had histologically verified bladder recurrence; 102 patients were positive, of 22 had bladder recurrence. Kaplan–Meier analysis showed that patients with positive FISH result were more likely to present bladder recurrence (p = 0.077, Figure 1A). However, positive FISH was not related to cancer specific-free survival (CSS) (p = 0.944, Figure 1B).

Tumor multifocality, the percentage of abnormal chromosome 3 > 5%, chromosome 7 > 6%, chromosome 17 > 11% and deletion of p16 > 4% were prognostic risk factors for BRFS in univariate analysis (Figure 2A–2D).

DISCUSSION

UTUC is a comparatively rare cancer. The common diagnosis methods mainly included computed tomography/magnetic resonance imaging, cystoscopy, urinary cytology and diagnostic ureteroscopy. About 15–25% of bladder lesions are muscle invasive, while 60% of UTUC are invasive at initial diagnosis as well as patients with UTUC had comparatively poor prognosis [12]. The prognostic factors for UTUC included acknowledged tumor stage and grade, lymphovascular invasion status, lymph node involvement, tumor size, hydronephrosis, tumor multifocality and necrosis [12]. In addition, European Association of Urology Guidelines reviewed several literatures and reported that four nomograms were currently available to predict survival rates post-operatively, based on standard pathological features [13–16]. Several studies had demonstrated that ureteroscopy increased the risk of bladder recurrence [17, 18], but urinary markers which could predict tumor recurrence were relatively few. Nobuyuki Tanaka et al. [19] retrospectively collected 474 patients with non-metastatic UTUC and found post-operative positive urine cytology was correlated with the occurrence rate of intravesical relapse after RNU. Kobayashi et al. [20] reported that urine cytology with positive result was a independent prognostic marker for intravesical relapse using a cohort of 252 UTUC patients. Our previous study [8] suggested that positive FISH result of urine implied invasive UTUC (sensitivity for muscle-invasive and high grade UTUC, 71.70% and 76.47%, respectively) and this result gave aid to the clinical urological surgeon to select an appropriate operation method. However, the connection between FISH results and survival or progression of UTUC patients was unclear. Based on above study, we established this research to assess the influence of positive FISH on oncological outcomes in UTUC.

In this research, the results showed that patients with positive FISH were more likely to experience bladder recurrence. Casey Seideman et al. [11] reported that FISH result could accurately predict intravesical recurrence for those patients with bladder cancer. Jared Whitson et al.
| Variables                        | N (%) or Median (range) |
|---------------------------------|-------------------------|
| N (%)                           | 159                     |
| Gender                          |                         |
| Male                            | 78(49.1)                |
| Female                          | 81(50.9)                |
| Age                             | 70(31–87)               |
| Hydronephrosis                  |                         |
| Present                         | 19(11.9)                |
| Absent                          | 140(88.1)               |
| Tumor location                  |                         |
| Pelvis                          | 81(50.9)                |
| Ureter                          | 71(44.7)                |
| Both                            | 7(4.4)                  |
| Tumor stage                     |                         |
| A                               | 12(7.5)                 |
| 1                               | 70(44.0)                |
| 2                               | 39(24.5)                |
| 3                               | 37(23.3)                |
| 4                               | 1(0.6)                  |
| Tumor grade                     |                         |
| Low                             | 86(54.1)                |
| High                            | 73(45.9)                |
| Lymph node status               |                         |
| cN0 or pN0                      | 152(95.6)               |
| N+                              | 7(4.4)                  |
| LVI                             |                         |
| Presence                        | 139(87.4)               |
| Absence                         | 20(12.6)                |
| Tumor size                      |                         |
| ≤ 3 cm                          | 90(56.6)                |
| > 3 cm                          | 69(43.4)                |
| Multifocal                      |                         |
| Yes                             | 136(85.5)               |
| No                              | 23(14.5)                |
| FISH                            |                         |
| Positive                        | 102(64.2)               |
| Negative                        | 57(35.8)                |
| FISH probe                      |                         |
| CH3 abnormal, %                 | 7(0–46)                 |
| CH7 abnormal, %                 | 7(0–38)                 |
| CH17 abnormal, %                | 8(0–53)                 |
| p16 loss, %                     | 7(0–65)                 |
| Outcome                         |                         |
| Follow-up, months               | 27(3–55)                |
| Time to recurrence, months      | 11(1–43)                |
| Time to death, months           | 15.5(3–38)              |

LVI = lymphovascular invasion; FISH = fluorescence in situ hybridization; CH = chromosome.
reported that patients with high-risk bladder diseases were more likely to relapse when they had positive FISH results. Massimo Maffezzini et al. [21] analyzed 126 patients diagnosed with non-muscle invasive bladder cancer (NMIBC) and observed that FISH-positive results was highly predictive of relapse. Our result determined the prognostic significance of FISH for predicting oncologic outcome. Recent fundamental research suggested that the luminal seeding and implantation hypothesis played a major role in bladder recurrence [22, 23]. This hypothesis mainly asserted that the multifocal development including simultaneous and metachronous tumor was caused by the planting or intraepithelial diffusion tumor cells. Since positive FISH result were associated with higher stage and grade tumor which presented more aggressive, the patients with positive FISH result possibly had higher degrees of intravesical exposure. Therefore, it was reasonable that positive FISH patients tend to relapse in bladder.

In this cohort, we were the first to define the cutoff value of preoperative FISH test probe as a predictive indicator of bladder recurrence. In univariate analysis, tumor multifocality, the percentage of abnormal chromosome 3 > 5%, chromosome 7 > 6%, chromosome 17 > 11% and deletion of p16 > 4% were correlated with BRFS. In multivariate analysis, only tumor multifocality and p16 loss > 4% were prognostic factors for BRFS. The 9p21 which contained p16/CDKN2 and p14ARF site located in chromosome 9 short arm and mainly participated in regulating cell circle and cell death [24, 25]. The loss of 9p21 leads to the p16 gene non-functional, and then disorder cell cycle resulting in disease relapse [26].

| FISH probe | N(%) | Cancer specific death | Recurrence |
|------------|------|-----------------------|------------|
| FISH Positive | 102(64.2%) | 16(15.7%) | 22(21.6%) |
| FISH Negative | 57(35.8%) | 10(17.5%) | 6(10.5%) |
| CH3 abnormal ≤ 5% | 62(39.0) | 11(17.7%) | 5(8.1%) |
| CH3 abnormal > 5% | 97(61.0) | 15(15.5%) | 23(23.7%) |
| CH7 abnormal ≤ 6% | 77(48.4) | 15(19.5%) | 9(11.7%) |
| CH7 abnormal > 6% | 82(51.6) | 11(13.4%) | 19(23.2%) |
| CH17 abnormal ≤ 11% | 98(61.6) | 15(15.3%) | 13(13.3%) |
| CH17 abnormal > 11% | 61(38.4) | 11(18.0%) | 15(24.6%) |
| p16 loss ≤ 4% | 60(37.7) | 6(10.0%) | 4(6.7%) |
| p16 loss > 4% | 99(62.3) | 20(20.2%) | 24(24.2%) |

FISH: fluorescence in situ hybridization; CH: chromosome.

Table 2: Clinical outcome in 159 assessable patients during median follow-up of 28 months

| Preoperative factors | T2-T4 | Tumor high grade |
|---------------------|-------|------------------|
|                     | Univariate | Multivariate | Univariate | Multivariate |
| Gender (male vs female) | 2.752 | 0.097 | 1.483(0.748–2.938) | 0.259 | 0.143 | 0.095(0.483–1.892) | 0.897 |
| Age (≤ 70 vs > 70) | 1.388 | 0.239 | 1.562(0.797–3.063) | 0.194 | 2.191 | 1.039(0.489–2.213) | 0.922 |
| Hydronephrosis (absence vs absence) | 1.875 | 0.171 | 0.517(0.479–4.322) | 0.517 | 0.018 | 0.892 | 1.283(0.442–3.724) | 0.647 |
| Tumor location (both or ureter vs pelvis) | 1.239 | 0.538 | 1.679(0.392–3.166) | 0.327 | 3.915 | 1.014 | 1.518(0.820–2.813) | 0.184 |
| Tumor size (≤ 3 cm vs > 3 cm) | 2.155 | 0.142 | 1.679(0.836–3.372) | 0.146 | 0.180 | 0.671 | 1.060(0.530–2.119) | 0.869 |
| Multifocal (presence vs absence) | 0.705 | 0.401 | 1.167(0.451–3.018) | 0.751 | 1.219 | 0.270 | 1.529(0.592–3.950) | 0.381 |
| CH3 abnormal (≤ 5% vs > 5%) | 0.969 | 0.325 | 0.802(0.282–2.284) | 0.680 | 3.180 | 0.075 | 1.099(0.392–3.081) | 0.858 |
| CH7 abnormal (≤ 6% vs > 6%) | 1.855 | 0.173 | 0.584(0.179–1.906) | 0.373 | 2.905 | 0.088 | 0.674(0.210–2.160) | 0.506 |
| CH17 abnormal (≤ 11% vs > 11%) | 5.925 | 0.015 | 3.027(1.059–8.650) | 0.039 | 3.848 | 0.050 | 1.436(0.518–3.979) | 0.487 |
| p16 loss (≤ 4% vs > 4%) | 3.932 | 0.047 | 1.762(0.709–4.381) | 0.223 | 7.875 | 0.005 | 2.279(0.918–5.658) | 0.076 |

HR = hazard ratio; CI = confidence interval; CH: chromosome.
Figure 1: Bladder recurrence-free survival and cancer specific-free survival stratified by FISH result. (A) Kaplan-Meier plot of recurrence-free survival curves stratified by positive and negative FISH ($p = 0.077$). (B) Kaplan-Meier plot of cancer specific-free survival curves stratified by positive and negative FISH ($p = 0.944$).

Figure 2: Kaplan-Meier plot of Bladder recurrence-free survival stratified by the percentage of copy number aberrations of (A) chromosomes 3 ($p = 0.012$), (B) chromosomes 7 ($p = 0.036$), (C) chromosomes 17 ($p = 0.028$) and (D) p16 loss ($p = 0.005$).
Table 4: Univariate and multivariate analysis of CSS and BRFS

| Variable                  | CSS       | BRFS       |                  | CSS       | BRFS       |                  |
|---------------------------|-----------|------------|------------------|-----------|------------|------------------|
|                           | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate |
|                           | HR(95%CI) | P          | HR(95%CI) | P          | HR(95%CI) | P          |
| Gender                    |           |            |           |            |           |            |
| Male                      | 2.131     | 0.067      | 1.823     | 0.122      |           |            |
| Female                    | (0.949–4.782) |        | (0.852–3.901) |        |            |            |
| Age                       | 0.999     | 0.943      | 0.975     | 0.146      |           |            |
|                           | (0.960–1.038) |        | (0.942–1.009) |        |            |            |
| Hydronephrosis            | 1.490     | 0.464      | 1.199     | 0.740      |           |            |
| Present                   | (0.512–4.336) |        | (0.411–3.497) |        |            |            |
| Absent                    |           |            |           |            |           |            |
| Tumor location            | 1.709     | 0.098      | 1.297     | 0.420      |           |            |
| Pelvis                    | (0.906–3.224) |        | (0.690–2.439) |        |            |            |
| Ureter                    |           |            |           |            |           |            |
| Both                      |           |            |           |            |           |            |
| Tumor stage               | 6.507     | **< 0.001** | 6.087     | **< 0.001** | 1.572     | 0.281      |
| T1&T2                     | (2.962–14.296) |        | (2.766–13.395) |        | (0.691–3.575) |        |
| T3&T4                     | 2.898     | **0.012**  | 1.224     | 0.593      |           |            |
|                           | (1.260–6.667) |        | (0.583–2.573) |        |            |            |
| Tumor grade               | 3.773     | **0.031**  | 0.811     | 0.837      |           |            |
| High                      | (1.125–12.648) |        | (0.110–5.969) |        |            |            |
| Low                       |           |            |           |            |           |            |
| Lymph node status         | 3.867     | **0.002**  | 2.216     | 0.086      |           |            |
| cN0 or pN0                | (1.674–8.936) |        | (0.894–5.488) |        |            |            |
| N+                        |           |            |           |            |           |            |
| LVI                       | 3.889     | **0.015**  | 2.425     | 0.032      | 0.915     | 0.819      |
| Presence                  | (1.214–6.137) |        | (1.077–5.458) |        | (0.428–1.957) |        |
| Absence                   |           |            |           |            |           |            |
| Tumor size                | 1.889     | 0.172      | 3.808     | **0.001**  | 3.487     | 0.002      |
| ≤3cm                      | (0.758–4.709) |        | (1.756–8.258) |        | (1.605–7.576) |        |
| >3cm                      |           |            |           |            |           |            |
| Multifocal                |           |            |           |            |           |            |
| Yes                       | 0.883     | 0.754      | 3.204     | **0.018**  |           |            |
| No                        | (0.405–1.924) |        | (1.217–8.343) |        |            |            |
| Ch3 abnormal              |           |            |           |            |           |            |
| ≤ 5%                      | 0.762     | 0.494      | 2.283     | **0.042**  |           |            |
| > 5%                      | (0.349–1.662) |        | (1.029–5.065) |        |            |            |
| Ch7 abnormal              |           |            |           |            |           |            |
| ≤ 6%                      | 1.386     | 0.413      | 2.260     | **0.033**  |           |            |
| > 6%                      | (0.634–3.030) |        | (1.070–4.774) |        |            |            |
| Ch17 abnormal             |           |            |           |            |           |            |
| ≤ 11%                     | 2.288     | 0.076      | 4.065     | **0.009**  | 3.766     | 0.014      |
| > 11%                     | (0.918–5.706) |        | (1.410–11.718) |        | (1.303–10.884) |        |
| p16 loss                  |           |            |           |            |           |            |
| ≤ 4%                      |           |            |           |            |           |            |
| > 4%                      |           |            |           |            |           |            |

CSS: Cancer Specific-free Survival; BRFS: Bladder Recurrence-free Survival; LVI: lymphovascular invasion; CH: chromosome.
patients were analyzed using UroVysion FISH kit; labeled evaluation FISH, treatment strategy and pathological patients provided written informed consent. All patients had received neoadjuvant chemotherapy. All 159 patients were retrospectively analyzed. None of the failures to follow up; 15 patients without information of previous or concomitant bladder tumors; 36 patients underwent surgeries for UTUC in the Urology Department, Peking University First Hospital between January 2012 and May 2016 were enrolled in this study. Seventy-three were subsequently removed from the analysis: 22 patients with previous or concomitant bladder tumors; 36 patients failed to follow up; 15 patients without information of FISH probe. Clinicopathologic data for the remaining 159 patients were retrospectively analyzed. None of the patients had received neoadjuvant chemotherapy. All patients provided written informed consent.

Follow-up

Follow-up including laboratory data, chest X-ray, urinary ultrasonography, computed tomography/magnetic resonance imaging and cystoscopic evaluation of the urinary bladder should be made every 3 months for the first 2 years, every 6 months until year 5, then annually. The co-primary endpoints of the study were bladder recurrence and cancer-specific death. Bladder recurrence was defined as finding bladder tumors at cystoscopic evaluation and the patients were performed transurethral resection of bladder tumor or radical cystectomy thereafter. Bladder recurrence-free survival (BRFS) and cancer-specific survival (CSS) were calculated from the date of surgery to the date of bladder recurrence and cancer specific death.

Statistical analysis

We used Mann-Whitney U and chi-squared tests to compare continuous and categorical variables, respectively. Binary logistic regression was used to evaluate preoperative factors. The probability of survival was calculated by the Kaplan–Meier method, with statistical differences evaluated by the log-rank test. Variables influencing BRFS and CSS were compared using Cox proportional hazards regression models. Variables with a \( p < 0.05 \) in univariate analysis were also assessed in multivariate analysis. All statistical analyses were performed using the IBM Statistical Package for Social Sciences (SPSS) version 22.0. For all statistical tests, two-sided \( p < 0.05 \) was considered to indicate statistical significance.

Author contributions

Bao Guan, Congyi Du and Xiaohong Su are co-first authors and contributed equally to the study. Liqun Zhou

MATERIALS AND METHODS

Patient selection

A total of 232 consecutive patients who underwent surgeries for UTUC in the Urology Department, Peking University First Hospital between January 2012 and May 2016 were enrolled in this study. Seventy-three were subsequently removed from the analysis: 22 patients with previous or concomitant bladder tumors; 36 patients failed to follow up; 15 patients without information of FISH probe. Clinicopathologic data for the remaining 159 patients were retrospectively analyzed. None of the patients had received neoadjuvant chemotherapy. All patients provided written informed consent.

FISH, treatment strategy and pathological evaluation

Voided urine specimens from the 159 UTUC patients were analyzed using UroVysion FISH kit; labeled probes specific for chromosomes 3, 7, and 17, and the p16 (9p21) genes were used to assess prognostic value. About 45 ml urine of each patient was collected using a 50 ml sterile centrifuge tube from 8:00 to 11:00 in the morning. The FISH assays were ordered based on provider’s protocol. Diagnosis criteria for positive FISH was described as previous study [8]. All UTUC patients who underwent conservative surgery or RNU were regularly followed according to institutional practice. In this cohort, one hundred and forty-two patients underwent RNU with an ipsilateral bladder cuff excision; the remaining 17 patients underwent conservative surgery, including ureteroureterostomy and complete distal ureterectomy and neocystostomy. All pathological specimens were reexamined by a dedicated genitourinary pathologist to confirm the original diagnosis. Tumor stage, grade, multifocality, tumor size and status of regional lymph nodes were described as previous study [8].
and Xuesong Li are corresponding authors and contributed to the overall study design. Zhenpeng Cao, Yifan Li, Yonghao Zhan, Ding Peng, Gengyan Xiong, Dong Fang, Yi Ding, Shiming He, Yanqing Gong, Qun He conducted to data collection, and analysis.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING

This work was supported by grants from the National Science Foundation of Beijing (7152146), the Clinical Features Research of the Capital (No. Z151100004015173) and the Capital Health Research and Development of Special (2016-1-4077).

REFERENCES

1. Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol. 2015; 68:868–79. https://doi.org/10.1016/j.eururo.2015.06.044.
2. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012; 62:100–14. https://doi.org/10.1016/j.eururo.2012.02.030.
3. Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF, Upper Tract Urothelial Carcinoma Collaboration. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012; 61:1069–70. https://doi.org/10.1016/j.eururo.2012.02.042.
4. Wang J, Wu J, Peng L, Tu P, Li W, Liu L, Cheng W, Wang X, Zhou S, Shi S, Ma H, Lu G, Zhou X. Distinguishing urothelial carcinoma in the upper urinary tract from benign diseases with hematuria using FISH. Acta Cytol. 2012; 56:533–8. https://doi.org/10.1159/000341622.
5. Xu C, Zeng Q, Hou J, Gao L, Zhang Z, Xu W, Yang B, Sun Y. Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients. Urology. 2011; 77:636–41. https://doi.org/10.1016/j.urology.2010.07.498.
6. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int. 2009; 104:336–9. https://doi.org/10.1111/j.1464-410X.2009.08375.x.
7. Lodde M, Mian C, Mayr R, Compljoe E, Trenti E, Melotti R, Campodonico F, Maffezzini M, Fritsche HM, Pycha A. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading. Int J Urol. 2014; 21:968–72. https://doi.org/10.1111/iju.12509.
8. Su X, Hao H, Li X, He Z, Gong K, Zhang C, Cai L, Zhang Q, Yao L, Ding Y, Gong Y, Fang D, Zhang Z, et al. Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma. Oncotarget. 2017; 8:26106–11. https://doi.org/10.18632/oncotarget.15344.
9. Garcia-Pelaez B, Trias I, Roman R, Pubill C, Banus JM, Puig X. Fluorescent in situ hybridization as a predictor of relapse in urothelial carcinoma. Actas Urol Esp. 2013; 37:395–400. https://doi.org/10.1016/j.acuro.2012.11.005.
10. Matsuyama H, Ikemoto K, Eguchi S, Oga A, Kawauchi S, Yamamoto Y, Kawai Y, Matsumoto H, Hara T, Nagao K, Sakano S, Sasaki K. Copy number aberrations using multicolour fluorescence in situ hybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC). BJU Int. 2014; 113:662–7. https://doi.org/10.1111/bju.12232.
11. Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I, Rao J, Imman BA, Posch M, Herr H, Lotan Y. Multicenter evaluation of the role of Urovysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol. 2015; 33:1309–13. https://doi.org/10.1007/s00345-014-1452-9.
12. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, Van Rhijn BW, Shariat SF, Soukup V, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017; 71:447–61. https://doi.org/10.1016/j.eururo.2016.05.041.
13. Ku JH, Moon KC, Jung JH, Jeong SH, Kwak C, Kim HH. External validation of an online nomogram in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Br J Cancer. 2013; 109:1130–6. https://doi.org/10.1038/bjc.2013.462.
14. Roupret M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol. 2013; 189:1662–9. https://doi.org/10.1016/j.juro.2012.10.057.
15. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bansalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, et al. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int. 2014; 114:733–40. https://doi.org/10.1111/bju.12631.
16. Yates DR, Hupertan V, Colin P, Ouzzane A, Descazeaud A, Long JA, Pignot G, Crouzet S, Rozet F, Neuzillet
Y, Soulie M, Bodin T, Valeri A, et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer. 2012; 106:1083–8. https://doi.org/10.1038/bjc.2012.64.

17. Luo HL, Kang CH, Chen YT, Chuang YC, Lee WC, Cheng YT, Chiang PH. Diagnostic ureteroscopy independently correlates with intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Ann Surg Oncol. 2013; 20:3121–6. https://doi.org/10.1245/s10434-013-3000-z.

18. Liu P, Su XH, Xiong GY, Li XS, Zhou LQ. Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma is Independently Associated with Intravesical Recurrence after Radical Nephroureterectomy. Int Braz J Urol. 2016; 42:1129–35. https://doi.org/10.1590/S1677-5538.IBJU.2015.0366.

19. Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotaka S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Oyama M, et al. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2014; 32:48 e19–26. https://doi.org/10.1016/j.urolonc.2013.07.003.

20. Kobayashi Y, Saika T, Miyaji Y, Saegusa M, Arata R, Akebi N, Takenaka T, Manabe D, Nasu Y, Kumon H. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol. 2012; 30:271–5. https://doi.org/10.1007/s00345-011-0731-y.

21. Maffezzini M, Campodonico F, Capponi G, Canepa G, Casazza S, Bandelloni R, Tamagno S, Puntoni M. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res. 2010; 30:4761–5.

22. Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int J Urol. 2005; 12:709–16. https://doi.org/10.1111/j.1442-2042.2005.01155.x.

23. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet. 1993; 342:1087–8.

24. Yeager T, Stadler W, Belair C, Puthveneettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 1995; 55:493–7.

25. Piaton E, Carre C, Advenier AS, Deccaussin-Petrucci M, Mege-Lechevallier F, Lantier P, Granier G, Ruffion A. p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma. Cancer Cytopathol. 2014; 122:211–20. https://doi.org/10.1002/cncy.21376.

26. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56:430–42. https://doi.org/10.1016/j.eururo.2009.06.028.

27. Zellweger T, Benz G, Cathomas G, Mihatsch MJ, Sulser T, Gasser TC, Bubendorf L. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer. 2006; 119:1660–5. https://doi.org/10.1002/ijc.21704.

28. Kawauuchi S, Sakai H, Ikemoto K, Eguchi S, Nakao M, Takihara H, Shimabukuro T, Furuya T, Oga A, Matsuyma H, Takahashi M, Sasaki K. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. Hum Pathol. 2009; 40:1783–9. https://doi.org/10.1016/j.humpath.2009.06.011.

29. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene. 1993; 8:1083–5.